Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has shared an announcement.
Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced the postponement of the re-election of its Board and Supervisory Committee, originally set to expire on November 22, 2025. The extension is necessary to ensure continued operations while preparations for the re-election are underway. The postponement will not affect the company’s normal operations, and current board members will continue their duties until new elections are held. The company is committed to complying with relevant regulations and fulfilling disclosure obligations.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a joint stock company based in the People’s Republic of China, operating in the pharmaceutical industry. The company is involved in the development and production of pharmaceutical products, focusing on innovative solutions to meet market demands.
Average Trading Volume: 483,809
For a thorough assessment of 2591 stock, go to TipRanks’ Stock Analysis page.